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Pseudomyxoma peritonei (PMP) is a rare neoplastic process characterised by progressive intra-abdominal dissemination of mucinous
tumour, and generally considered resistant to systemic chemotherapy. A phase II study in patients with advanced unresectable PMP
was undertaken to evaluate the combination of systemic concurrent mitomycin C (7mgm
 2 i.v. on day 1) and capecitabine
(1250mgm
 2 b.d. on days 1–14) in a 3-weekly cycle (MCap). Response was determined by semiquantitative assessment of disease
volume on serial computed tomographic (CT) scans and serum tumour marker (CEA, CA125, CA19-9) changes at 12 weeks.
Between 2003 and 2006, 40 patients were recruited through a national centre for the treatment of peritoneal surface tumours. At
baseline, 23 patients had progressive disease and 17 had stable disease. Of 39 assessable patients, 15 (38%, 95% confidence intervals
(CIs): 25, 54%) benefited from chemotherapy in the form of either reductions in mucinous deposition or stabilisation of progressive
pretreatment disease determined on CT scan. Notably, two patients, originally considered unresectable, following MCap and
re-staging underwent potentially curative cytoreductive surgery. Grade 3/4 toxicity rates were low (6%, 95% CIs: 4, 9%). Twenty out
of 29 assessed patients (69%, 95% CIs: 51, 83%) felt that their Global Health Status improved during chemotherapy. This is the first
trial to demonstrate an apparent benefit of systemic chemotherapy in patients with advanced unresectable PMP.
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Pseudomyxoma peritonei (PMP) is a rare neoplastic process
(approximately 1–2 per million per year), arising in the majority
of cases from the appendix, defined by disseminated peritoneal
mucinous tumour deposition and progressive accumulation of
mucinous ascites (Renehan et al, 2008). Since mid 1990s, aggres-
sive cytoreductive surgery with removal of all visible macroscopic
disease, followed by hyperthermic intraperitoneal chemotherapy
(HIPEC) – often referred to as the ‘Sugarbaker’ procedure – has
been promulgated as standard care (Sugarbaker, 2006). However,
complete cytoreduction is possible in only one-third of cases at
presentation (Rout et al, 2008). Disease features that prohibit
complete cytoreduction include gastric encasement, diffuse small
bowel mesenteric involvement and fistulation (Sugarbaker and
Chang, 1999). For such advanced unresectable cases, debulking
surgery may offer symptomatic relief, but is associated with
considerable morbidity and mortality (Murphy et al, 2007;
Smeenk et al, 2007).
Conventionally, PMP is considered resistant to systemic
chemotherapy, and, to date, there are no published chemotherapy
trials in the setting of advanced unresectable disease. However, a
recent report described a patient with PMP responding to
capecitabine – an oral fluoropyrimidine (Levitz et al, 2004). Given
this, and the following rationales: (i) mitomycin C (MMC) and
5-fluorouracil (5-FU) are administered as HIPEC in the manage-
ment of PMP (Witkamp et al, 2001; Sugarbaker, 2006); (ii) MMC is
an established antitumour agent against gastrointestinal cancers
(Crooke and Bradner, 1976; Ozawa et al, 1988); and (iii) oral
capecitabine has equivalence effectiveness to bolus intravenous
5-FU/folinic acid in the treatment of metastatic colorectal cancer
(Hoff et al, 2001; Van Cutsem et al, 2001), but with better patient
acceptance (Borner et al, 2002), we hypothesized that a combina-
tion of concurrent MMC and capecitabine (MCap) would benefit
patients with advanced PMP. Furthermore, this regimen is effective
in advanced colorectal cancer (Rao et al, 2004).
The aim of this study was to undertake a phase II study to
evaluate tumour response, survival, toxicity and quality of life
in patients undergoing MCap chemotherapy for advanced
unresectable PMP.
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Patients
Between April 2003 and December 2006, patients referred with
histologically confirmed PMP to the Peritoneal Tumour Service of
Christie Hospital NHS Foundation Trust (Manchester, UK), one of
the two national centralised centres in the UK, and considered
unresectable by a dedicated PMP multidisciplinary team meeting,
were considered for this trial. Unresectability was determined
by predefined criteria on oral contrast computed tomography
(CT) scan, namely, gastric encasement, extensive small bowel
mesenteric involvement and/or fistulating disease, supplemented
wherever possible by pre-referral operative records and/or intra-
operative photographs. Histological classification was described by
Ronnett et al (1997),–namely, disseminated peritoneal adeno-
mucinosis (DPAM), peritoneal mucinous carcinomatosis (PMCA)
and PMCA with intermediate or discordant features (PMCA-I/D).
The trial was conducted with local ethical approval, in accordance
with accepted standards of good clinical practice, and in agreement
with the Declaration of Helsinki.
Inclusion and exclusion criteria
The inclusion criteria were as follows: age X18 years, World
Health Organisation performance status 0–2 and life expectancy
43 months. All patients were required to have adequate
haematological function (neutrophil count X1.5 10
9 per l and
platelet count X150 10
9 per l), hepatobiliary function (serum
bilirubin p1.5 upper limit of normal (ULN); ALP p5 ULN;
transaminase (AST or ALT) p3 ULN) and renal function
(estimated Cockcroft clearance X50mlmin
–1). Advice about
contraceptive precautions was given, and for women of child-
bearing potential, a negative pregnancy test was required.
The exclusion criteria were as follows: previous MMC or
5-FU-based systemic chemotherapy; concurrent uncontrolled
medical illness, including cardiac disease, and previous or
concurrent malignant disease; evidence of bowel obstruction;
chronic diarrhoea; or if women were pregnant or lactating.
Patients who had experienced life-threatening toxicities with
fluoropyrimidine treatment or had any condition that might affect
the absorption of capecitabine were also excluded. Patients on
warfarin anticoagulation were changed to low-molecular-weight
heparin (enoxaparin sodium) at the appropriate therapeutic dose.
Treatment
The MCap regimen consisted of MMC 7mgm
 2 intravenous
injection on day 1 and capecitabine 1250mgm
 2 twice daily on
days 1–14, with a break in treatment on days 15–21. The next
cycle consisted solely of capecitabine 1250mgm
 2 twice daily on
days 1–14, with a break in treatment on days 15–21. These 3-week
cycles were alternated so that eight cycles were given in total (four
of each) (Figure 1). Prophylactic anti-emetics (ondansetron 8mg)
were administered intravenously along with MMC. Patients were
treated for at least 12 weeks (4 3-weekly cycles) prior to response
evaluation.
Assessment of tumour response and toxicity
Patients were assessed at baseline and every 3 weeks and the
following parameters recorded: performance status, weight,
abdominal girth and toxicity scored using the National Cancer
Institute’s Common Terminology Criteria for Adverse Events
version 3.0 (NCI, 2004). The following serum tumour markers were
determined: carcinoembryonic antigen (CEA), cancer antigen
125 (CA125) and cancer antigen 19-9 (CA19-9).
A CT (axial computed tomography) scan was performed at
baseline, and at the end of cycles 4 (12 weeks) and 8 (24 weeks).
Standard CT scan RECIST criteria for the assessment of disease
response were not applicable, as disease characteristics, such as
cystic areas and ascites, are not included in these criteria (Padhani
and Ollivier, 2001). Instead, using parallel matched computer
monitors of serial CT scans, tumour response was determined
semiquantitatively as either stable, reduced or progressed.
Chemotherapy was administered unless a criterion for study
discontinuation was met. Treatment was stopped at the request of
the patient for any reason, or if, in the opinion of the investigator,
it was in the patient’s best interest to do so. At each review, a score
of toxicity criteria was made according to NCI-CTCAE documents.
Patients were treated only if all of these toxicity criteria were grade
1 or less. Patients with persistent grade 2 symptoms were deferred
until their symptoms had improved to at least grade 1. If patients
experienced grade 3 or 4 toxicity, then chemotherapy was delayed
until their symptoms had resolved to grade 1 or better. Further
doses of capecitabine and MMC were then reduced by 20% and
this was continued for the rest of the course.
Assessment of quality of life
Quality of life was assessed using the European Organization for
Research and Treatment of Cancer (EORTC) questionnaires QLQ-
C30 (version 3) (Aaronson et al, 1993) and QLQ-CR38 (version 3)
(Sprangers et al, 1999) at baseline, at 6 weeks and then every
12 weeks during the chemotherapy course.
Statistical analysis
Data were collected prospectively and analysed using SPSS version
14.0
s (Superior Performing Software Systems, Chicago, IL, USA).
95% confidence intervals (CIs) for single proportions were
estimated using the Wilson score method without continuity
correction (Newcombe, 1998). The Wilcoxon matched-pairs
signed-rank test was used to compare pre- and post-treatment
changes in tumour markers and quality of life data from the
EORTC questionnaires QLQ C30 and CR38. Survival estimates
were calculated by using the Kaplan–Meier method. Statistical
significance was taken as Pp0.05.
As there was no precedent, a response rate of at least 20% was
considered to be acceptable in this study. Therefore, 14 patients
were treated in the first instance and the study was extended on the
response measured in that group. Only patients receiving the first
12 weeks of treatment were included in the assessment of the
objective response rate. As more than 1 out of the first 14 patients
1 Cycle
Week
Week
MMC – Mitomycin C at 7mg m–2
CAP – Capecitabine at 1250mg m–2
Cycle
MMC MMC
CAP
CAP CAP CAP CAP CAP CAP CAP CAP
MMC MMC
CAP CAP CAP CAP CAP CAP CAP
234 Assessment
CT 
TM 
QoL
12 11 10
24 23 22 21 20 19 18 17 16 15 14 13
9 8
8 7 6 5
7 6 5 4 3 2 1
CT 
TM 
QoL
Figure 1 The MCap chemotherapy regimen. CT, CT scan at baseline
and then 3-monthly; TM, tumour markers: CA125, CA19.9, CEA; QoL:
quality of life data collected at each cycle.
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measurable response was 27 and the maximum 40 in order to give
an estimate of the true response rate to a s.d. of 7.5%.
RESULTS
Forty patients were recruited to the trial. Baseline characteristics
are shown in Table 1. Over one-half of the participants were
female; all but one patient had undergone laparotomy elsewhere
prior to referral; and two-thirds were histologically classified as
DPAM. Two patients underwent laparotomy at our centre with a
view to complete cytoreduction but were considered unresectable
at operation and referred to the trial.
Tumour response and survival
The flow diagram of disease status at baseline and subsequent
responses to treatment are shown in Figure 2. Out of the 40
patients who started treatment with MCap chemotherapy,
23 (58%) had progressive disease and 17 (42%) had stable disease
at baseline measurements (Figure 2).
Out of the 23 patients with progressive disease prior to trial
entry, 19 patients received 3 months of treatment and 15
completed a full course of chemotherapy over 6 months. One
patient had a fit during the first cycle and had no further treatment
and was therefore not assessable for response. Three patients
(14%) responded to the treatment with a reduction in the volume
of mucus, and one of these patients also had a reduction in the
volume of the solid component of their disease. After 6 months of
chemotherapy, these patients had a sustained reduction in disease
and nine patients (41%) were found to have stable disease. These
patients had progressive disease prior to chemotherapy (Figure 2).
Prior to treatment, two patients had mucous discharge of
approximately 50 mlday
 1 from cutaneous fistula/sinuses. In one
patient, the discharge settled completely with the cutaneous
opening healing after 3 months of treatment. Another patient
had two sinuses at the start of the treatment. After chemotherapy,
one of the sinuses was dry and discharge from the other reduced
from 50mlday
 1 to approximately 20mlday
 1. There was also a
change in the consistency of the discharge from mucoid to serous
(Figure 3).
Out of the 17 patients with stable disease prior to trial entry,
16 patients completed a full course of treatment. At 3 months, all
17 patients were receiving chemotherapy and were therefore
assessable. Three patients (18%) responded to treatment with a
reduction in the volume of mucus, which was maintained at
6 months. At this time point, nine patients (53%) were found to
have stable disease and five (29%) were found to have progressive
disease (Figure 2).
Overall, out of the 39 assessable patients, 15 (38%) benefited
from the chemotherapy regimen in terms of a reduction in mucus
(with or without a solid component) or development of stability
when known to be progressing prior to treatment (Figure 2).
Patients who had stable disease prior to starting treatment and had
maintained stable disease during chemotherapy were considered
to have received no added benefit from this therapy.
With a median follow up of 17 months (range 3.3–34.0), the
1-year and 2-year tumour-related survival rates for the 40 patients
were 84% and 61%, respectively (Figure 4).
Tumour marker response
At baseline measurement, at least one serum tumour marker was
raised in all patients and all three tumour markers were raised in
13 patients (33%, 95% CIs: 20, 48%). For those patients who
completed a full chemotherapy course, there were reductions in
the tumour marker levels by more than 50% for CEA in 11
patients; CA125 in 7 patients and CA19-9 in 6 patients. Twenty
patients (51%, 95% CIs: 36, 66%) had a reduction in one or more
tumour markers by more than 50% with chemotherapy. Overall,
there were statistically significant reductions in the concentrations
of CEA (P¼0.001) and CA125 (P¼0.002), but not CA19-9,
between pre- and post-trial values (Figure 5). However, there were
no differences in pre- and post-chemotherapy tumour marker
changes when stratified by tumour response, histological type and
whether progressive or stable disease at baseline. Weight,
abdominal girth and performance status, which were measured
at each cycle, did not alter significantly, and were not related with
patient’s response to treatment.
Table 1 Baseline patient characteristics
n
a (%)
Patients 40
Median age (range), years 59 (32–77)
Males/females 12:28
Histological group
DPAM 27 (68)
PMCA-I/D 10 (25)
PMCA 3
Previous laparotomies
No previous laparotomies 1
1 22 (55)
2 12 (30)
X35
WHO performance status
0 36 (90)
12
22
DPAM¼disseminated peritoneal adenomucinosis; PMCA¼peritoneal mucinous
carcinomatosis; PMCA-I/D¼PMCA with intermediate or discordant features.
aNumber of patients unless otherwise stated.
Progressive disease
n = 23
Tumour reduction
n = 3
Tumour stable
n = 9
Tumour progression
n = 6; died n = 4
Stable disease
n = 17
Tumour reduction
n = 3
Tumour stable
n = 9
Tumour
progression
n = 5
One not assessable
2003 – 2006
n = 40
Figure 2 Flow diagram of treatment response. Response determined by
CT scan during chemotherapy at 12 and 24 weeks and then confirmed at
6 months.
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There were no treatment-related mortalities; four patients (all in
the progressive disease group at baseline) died early during
their treatment due to disease progression; three of them had
either PMCA-I/D or PMCA histological subtypes. Thirty-one
patients (78%, 95% CIs: 63, 88%) completed 24 weeks of MCap
chemotherapy. One patient suffered an epileptic fit during the first
cycle and had no further treatment. Three patients stopped
chemotherapy after the interim scans showed progressive disease;
one patient stopped before the final cycle due to grade 3 toxicity.
Grade 3 toxicities occurred in 12 out of 277 cycles; grade 4
toxicities in 4 out of 277 cycles – an overall rate of 6% (95% CIs:
4, 9%). All these toxicities were the hand and foot syndrome
(Table 2).
Repeat MCap chemotherapy
Despite disease progression, 17 patients had a repeat MCap
chemotherapy. Of these, 7% (41, 95% CIs: 22, 64%) achieved
disease stabilisation. The maximum amount of MMC given was 6
doses of 7mgm
 2 (42mgm
 2 total) – no cumulative MMC toxicity
was evident. After this, patients were only treated with capecita-
bine at the same dose. Notably, two patients, originally considered
unresectable, following MCap and re-staging underwent
potentially curative cytoreductive surgery.
Quality of life
Overall, quality-of-life parameters remained stable, with only the
Global Health Status and chemotherapy-related side effects
showing some alteration with treatment. The Global Health Status
(QL2) provides an insight into a patients overall feeling about their
Pretreatment Post-treatment
Figure 3 Computed tomographic scan of the abdomen at baseline and after the full treatment in a patient with initially progressive disease that shows
a reduction in size of the retroperitoneal collection (arrows).
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Figure 4 Survival curve for patients receiving MCap chemotherapy using
Kaplan–Meier plot.
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Figure 5 Percentage change in tumour marker level from baseline to
post-treatment. Analysis limited to patients who completed a full course.
CEA, carcinoembryonic antigen (normal range o3mgl
 1); CA125, cancer
antigen 125 (normal range o30Uml
 1); CA19-9, cancer antigen (normal
range o31Uml
 1).
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progressive disease prior to chemotherapy who completed a full
course, 10 (67%) felt that their Global Health Status was the same
or better at the end of the course, but 4 felt that it was worse
(1 patient did not complete the form). Out of the 16 patients with
initially stable disease prior to chemotherapy who completed a full
course, 10 (63%) felt that their Global Health Status was the same
or better at the end of the course, but 5 felt that it was worse
(1 patient did not complete the form). Analysis of data from
each section of the questionnaire showed that the only statistically
significant reduction in a specific area of quality of life was
chemotherapy-related side effects (P¼0.005). There was no
statistically significant difference in change in quality of life
during the chemotherapy course stratified by initial disease status
(stable vs progressive).
DISCUSSION
This is the first evaluation of systemic chemotherapy in patients
with advanced unresectable PMP. Within the limitation of a non-
randomised design, the data show that over one-third of patients
appear to benefit from treatment with MCap chemotherapy
without high rates of severe toxicity or reduction in quality of life.
A potential limitation of the study was the failure to quantify
disease response using volume-based criteria. The role of CT
scanning is well outlined for initial diagnosis. Early disease is
characterised by an appendiceal tumour, and deposits predomi-
nantly on the diaphragmatic surface, around the liver and spleen
and within the pouch of Douglas; as the disease progresses,
deposits around the liver and spleen show scalloping and compress
the adjacent organs, particularly the stomach (Sulkin et al, 2002).
On contrast enhanced CT, PMP deposits are predominantly of low
density, but may show septa and solid elements, likely to represent
mucinous tumour deposits, encysted collections of mucin and
fibrosis. Because of the diffuse nature of the disease, measurement
of PMP disease volume is challenging. The RECIST criteria are not
applicable, as these specifically exclude ascites and cystic areas
as measurable lesions (Padhani and Ollivier, 2001). Changes in
volume of disease within the peritoneal cavity may be assessed in
some cases by measurement of relatively well-defined deposits
(encysted mucin) or by measurement of the radial diameter
of deposits over the surface of the liver or spleen. However,
where there are diffuse deposits, volume of disease cannot be
meaningfully assessed using unidimensional or bidimensional
measurements. Moreover, apparent changes in the burden of
intraperitoneal disease may reflect changes in the volume of
mucinous ascites and not of solid tumour. The baseline scan and
all subsequent scans were carried out at Christie Hospital using the
same protocol. All scans were reported by radiologists who are
experienced in the radiological evaluation of PMP.
In an effort to overcome these potential limitations, CT assess-
ment of treatment was approached systematically using three
criteria: (i) overall assessment of the disease volume including
mucin (supported by measurement of discrete deposits where
possible); (ii) recording of new disease sites and (iii) the extent of
compressive effects of disease on intraperitoneal organs, for
example, degree of scalloping of the liver and spleen, compression
of the stomach and strictures of the small or large bowel. Decreases
in volumes of mucin alone were not recorded as responses.
The present study has a number of advantages. First, data on
treatment responses, survival, toxicity and quality of life were
collected prospectively. Second, uniform criteria were used to
report histological classifications and radiological responses.
Third, the study was set within the framework of a dedicated
Peritoneal Tumour Multidisciplinary meeting (Rout et al, 2008),
which assesses resectability and directs patients along appropriate
clinical pathways. This achievement was brought about through
the establishment of two centralised national treatment services –
Christie Hospital NHS Foundation Trust (Manchester, UK) and
North Hampshire Hospitals NHS Foundation Trust (Basingstoke,
UK) (Moran, 2006)–commissioned by the UK National Health
Service (NHS) National Commissioning Group for Highly
Specialised Services. This funding system circumnavigates many
logistic problems of undertaking a trial in a rare tumour.
We explored whether serum tumour markers, namely CEA,
CA125 and CA19-9, may be helpful in the prediction of response to
systemic chemotherapy. We rationalised the following: (i) serum
CEA and CA19-9 levels are elevated in over 50% PMP patients at
presentation and drop markedly following cytoreductive surgery
and HIPEC (van Ruth et al, 2002); (ii) elevated CA 19-9 levels prior
to cytoreductive surgery may be an independent predictor of worse
progression-free survival (Baratti et al, 2007); and (iii) in a case
study of a patient with DPAM treated with capecitabine, there was
a decrease in CEA and CA19-9 levels (Levitz et al, 2004). Serum
CA125 concentrations are commonly raised in patients with PMP,
and at initial presentation, may mimic gynaecological malignan-
cies (Pranesh et al, 2005). However, it is noteworthy that serum
CA125 levels may also be raised in conditions including peritoneal
irritation (Sjovall et al, 2002), pelvic inflammatory disease (Halila
et al, 1986) and benign hepatic disease (Topalak et al, 2002).
Although our study demonstrated elevated levels of all three
markers in one-third of the cases at baseline, and reductions of
50% or more in half of these, there was no relationship between
treatment response and decrease in marker level. Although the
present study is relatively small, tumour marker response does not
appear helpful in determining chemotherapy response.
For an unselected population of patients with PMP, over half of
the cases at initial presentation will be advanced and unresectable.
For these, we recommend 3-monthly CT scan. Where disease
is stable, a ‘watch and wait’ policy with repeat imaging every
3–6 months may be prescribed. These patients should be
considered for MCap chemotherapy if they become symptomatic
or their disease is radiologically progressing. We recommend up to
a 6-month course of treatment followed by a rest period with CT
surveillance; repeat MCap courses may be prescribed if disease
progresses (the maximum total dose of MMC used in this study
was 42mgm
 2).
One unresolved questions from this study is that of optimising
patient selection criteria. We noted that three out of the four
patients that died early had aggressive histological types. Based
on its effectiveness in the management of advanced colorectal
cancer (Saunders and Iveson, 2006), we hypothesize that the use of
oxaliplatin and 5-FU combination may be beneficial in such cases.
This regimen has yet to be systematically tested and will have to
Table 2 Number and grade of toxicity events at each cycle during
course
Cycle 12345678
Evaluable patients 40 38 36 35 34 32 32 30
NCI-CTCAE grade 2 3 4 2 3 4 2 3 4 2 3 4 234234234234
Alopoecia
Anorexia 1
Constipation 1
Diarrhoea 3 1 2 1 1
H F S 3 24 43 1 4 1 7
Lethargy 5 1 798667
Nausea 1 1 2411 1
Neuropathy
Stomatitis 2 1 1
Vomiting 1 1 2 1 7
HFS¼hand and foot syndrome; NCI-CTCAE v3.0¼National Cancer Institute
Common Toxicity Criteria for adverse events.
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central venous access and cumulative toxicity such as parasthesia.
Although the understanding of the basic biology of PMP is still in
its infancy (Bibi et al, 2006), for the immediate future, systemic
antitumour approaches in the treatment of advanced unresectable
disease will probably emerge from existing strategies for related
gastrointestinal malignancies.
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